Obviously. It's a sign that regulators are taking the drug seriously.
OPT at the time of wAMD PhII results was a $200m company. Even though DXB is half of that now, doesn't mean we can't compare them in some ways.
DXB vs OPT pre release, page-4
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.5¢ |
Change
-0.015(3.19%) |
Mkt cap ! $250.3M | |||
| Open | High | Low | Value | Volume |
| 46.5¢ | 49.0¢ | 45.5¢ | $1.515M | 3.232M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 161532 | 45.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 46.5¢ | 33998 | 2 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| DXB (ASX) Chart |